Type
. Hansen's disease (Leprosy): current and future pharmacotherapy and treatment of disease-related immunologic reactions. Pharmacotherapy. 2012;32(1):27-37.
Type
. Lepra. 1stst ed. Suriname Informatie. Veka Productions; 2011.
Type
. Towards the molecular epidemiology of Mycobacterium leprae: strategies, successes, and shortcomings. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases. 2011;11(7):1505-13.
Type
. ML1419c peptide immunization induces Mycobacterium leprae-specific HLA-A*0201-restricted CTL in vivo with potential to kill live mycobacteria. Journal of immunology (Baltimore, Md. : 1950) [Internet]. 2011;187(3):1393-402. Available from: https://www.jimmunol.org/content/jimmunol/187/3/1393.full.pdf
Type
. Leprosy and HIV coinfection: a critical approach. Expert review of anti-infective therapy. 2011;9(6):701-10.
Type
. Crystalline deposition in the cornea and conjunctiva secondary to long-term clofazimine therapy in a leprosy patient. Indian journal of ophthalmology [Internet]. 2011;59(4):328-9. Available from: http://www.ijo.in/article.asp?issn=0301-4738;year=2011;volume=59;issue=4;spage=328;epage=329;aulast=Barot
Type
Surveillance of drug resistance in leprosy: 2010. Weekly epidemiological record [Internet]. 2011;86(23):237. Available from: http://www.who.int/wer/2011/wer8623.pdf
Type
. Leprosy statistics 2009: some thoughts. Leprosy review [Internet]. 2011;82(1):87-9. Available from: https://leprosyreview.org/article/82/1/08-7089
Type
. Report on the sixth meeting of the IDEAL (Initiative for Diagnostic and Epidemiological Assays for Leprosy) consortium held in Beijing, China on 23-25 August 2010. Leprosy review [Internet]. 2011;82(1):80-5. Available from: https://leprosyreview.org/article/82/1/08-0085
Type
. Reasons for interrupting multidrug therapy against leprosy: the patients' point of view. Leprosy review [Internet]. 2011;82(1):78-9. Available from: https://leprosyreview.org/article/82/1/07-8079